X-linked lymphoproliferative disease (XLP) is a congenital immunodeficiency that is
characterized by an abnormal immune response to primary Epstein-Barr virus (EBV) infection.
After EBV exposure, affected patients often develop fulminant infectious mononucleosis (FIM), a life-threatening condition marked by the uncontrolled expansion and activation of T and B lymphocytes and macrophages. We hypothesized that the rapid elimination of B cells immediately following EBV exposure might reduce the severity of primary EBV infection in XLP patients. To test this possibility, we administered the anti-CD20 antibody rituximab to 2 patients who presented with acute infection. Following treatment, both patients exhibited a complete resolution of symptoms and no longer demonstrated detectable EBV DNA within circulating lymphocytes. Moreover, neither patient has developed FIM or lymphoma in over 2 years of follow-up. These data suggest that the pre-emptive use of B cell-directed therapy may reduce the morbidity and mortality of primary EBV infection in XLP-affected individuals. siblings who had died from XLP. Previous genetic studies revealed that he carried a germline G383C SH2D1A mutation, which was predicted to lead to the substitution of arginine for serine at codon 28 of SAP 13 . Prior to the current illness, patient #1 had been healthy. He had received monthly intravenous (i.v.) gammaglobulin as prophylaxis against EBV infection.
At presentation, patient #1 showed a mild leukocytosis with a marked lymphocytosis ( Table I) .
Large granular lymphocytes and atypical lymphocytes were noted on a peripheral smear. Flow cytometric studies revealed an inverted CD4:CD8 ratio (1:4.4) with NK cells representing 10- 
Results and Discussion:
Allogeneic HSCT is the treatment of choice for the prevention of EBV-related morbidity and mortality in XLP [6] [7] [8] [9] [10] . For patients who do not undergo transplantation, acute EBV infection poses a therapeutic challenge as patients rapidly develop FIM. Antiviral therapies, such as acyclovir, ganciclovir and interferon-have not been successful in preventing or treating FIM 15, 16 . While steroids, etoposide and cyclosporine provide symptomatic benefit in some cases of EBV-induced hemophagocytosis 17, 18 , FIM remains the most common cause of death for XLP patients 1, 19 .
Work from several laboratories has shown that SAP-deficient T and NK cells exhibit defects in cytotoxic function and IFN production, factors that might interfere with clearance of EBVinfected B cells 5 . As persistence of these cells might subsequently promote the proliferation and activation of reactive T cells and macrophages, we hypothesized that the rapid eradication of EBV-infected B cells immediately after exposure might reduce viral burden and prevent the secondary hemophagocytic syndrome that typifies FIM. Because anti-CD20 immunotherapy
with rituximab leads to the elimination of more than 80% of circulating B cells within days 20 , we developed individualized therapies centered around this medication for 2 XLP patients presenting with acute EBV infection. These regimens varied slightly based on the preferences of treating oncologists, who were from different institutions. However, in both regimens, rituximab was combined with steroids to suppress T cell activation. Based on historical approaches, both regimens also included more traditional anti-viral agents, such as acyclovir and gancciclovir.
Following initiation of treatment, both patients demonstrated a rapid reduction of B cells to 1% or less of circulating lymphocytes (not shown). This decrease in B cell number was associated with a decline in peripheral blood leukocyte-associated EBV DNA to levels below the limit of detection (Figure 1) . In both patients, clinical improvement occurred within 24-48 hours, as was evident by a return to normal body temperature and disappearance of malaise and fatigue. Rituximab reduces the number of circulating B cells for up to 6 months or longer 20 . Although lymphomas are known to occur in EBV-positive and EBV-negative XLP patients, the development of lymphoma occurs earlier in EBV-infected individuals 21 . We do not know whether the reduction in B cell number that resulted following rituximab therapy will prevent the 
